TARGET THERAPY FOR PATIENTS WITH NEUROFIBROMATOSIS (LITERATURE REVIEW)
The relevance of the presented review is due to the high incidence of type 1 neurofibromatosis (NF1) and type 2 neurofibromatosis (NF2) in the population and frequent association with the development of malignant neoplasms. The purpose of the review is to analyze literature data that describe the re...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Science and Innovation Center Publishing House
2017-10-01
|
| Series: | В мире научных открытий |
| Subjects: | |
| Online Access: | http://journal-s.org/index.php/vmno/article/view/10208 |
| _version_ | 1818906185881878528 |
|---|---|
| author | Elena Vaycheslavovna Zhukovskaya Vladislav Pavlovoch Bondarenko Irina Ilinichna Spichak Ludmila Vasilevna Sidorenko |
| author_facet | Elena Vaycheslavovna Zhukovskaya Vladislav Pavlovoch Bondarenko Irina Ilinichna Spichak Ludmila Vasilevna Sidorenko |
| author_sort | Elena Vaycheslavovna Zhukovskaya |
| collection | DOAJ |
| description | The relevance of the presented review is due to the high incidence of type 1 neurofibromatosis (NF1) and type 2 neurofibromatosis (NF2) in the population and frequent association with the development of malignant neoplasms. The purpose of the review is to analyze literature data that describe the results of the use of targeted drugs for the treatment of neoplasms in patients with neurofibromatosis. The results of the literary search became a generalization of modern approaches to targeted therapy of neurofromatosis both NF1 and NF2 types. The results of the literary search became a generalization of modern approaches to targeted therapy of neurofromatosis both NF1 and NF2 types. Data on pharmacogenetics and the principles of etiopathogenetic therapy with the use of the following targeted therapy are presented: bevacizumab, erlotinib, imatinib, sorafenib, sirolimus. The summary table with the results of the survey contains information from 39 literature sources. According to the majority of authors, innovative target therapy of neurofibromatosis can be effective in many patients with advanced forms of the disease. |
| first_indexed | 2024-12-19T21:35:13Z |
| format | Article |
| id | doaj.art-74e1714457414fd496145a00503a34ac |
| institution | Directory Open Access Journal |
| issn | 2072-0831 2307-9428 |
| language | English |
| last_indexed | 2024-12-19T21:35:13Z |
| publishDate | 2017-10-01 |
| publisher | Science and Innovation Center Publishing House |
| record_format | Article |
| series | В мире научных открытий |
| spelling | doaj.art-74e1714457414fd496145a00503a34ac2022-12-21T20:04:48ZengScience and Innovation Center Publishing HouseВ мире научных открытий2072-08312307-94282017-10-019420521810.12731/wsd-2017-4-205-2186117TARGET THERAPY FOR PATIENTS WITH NEUROFIBROMATOSIS (LITERATURE REVIEW)Elena Vaycheslavovna Zhukovskaya0Vladislav Pavlovoch Bondarenko1Irina Ilinichna Spichak2Ludmila Vasilevna Sidorenko3НМИЦ ДГОИ им. Дмитрия Рогачева МЗ РоссииНМИЦ ДГОИ им. Дмитрия Рогачева МЗ РоссииОбластная детская клиническая больница им. Валентина ГерайнаНМИЦ ДГОИ им. Дмитрия Рогачева МЗ РоссииThe relevance of the presented review is due to the high incidence of type 1 neurofibromatosis (NF1) and type 2 neurofibromatosis (NF2) in the population and frequent association with the development of malignant neoplasms. The purpose of the review is to analyze literature data that describe the results of the use of targeted drugs for the treatment of neoplasms in patients with neurofibromatosis. The results of the literary search became a generalization of modern approaches to targeted therapy of neurofromatosis both NF1 and NF2 types. The results of the literary search became a generalization of modern approaches to targeted therapy of neurofromatosis both NF1 and NF2 types. Data on pharmacogenetics and the principles of etiopathogenetic therapy with the use of the following targeted therapy are presented: bevacizumab, erlotinib, imatinib, sorafenib, sirolimus. The summary table with the results of the survey contains information from 39 literature sources. According to the majority of authors, innovative target therapy of neurofibromatosis can be effective in many patients with advanced forms of the disease.http://journal-s.org/index.php/vmno/article/view/10208нейрофиброматозNF1NF2таргетная терапия |
| spellingShingle | Elena Vaycheslavovna Zhukovskaya Vladislav Pavlovoch Bondarenko Irina Ilinichna Spichak Ludmila Vasilevna Sidorenko TARGET THERAPY FOR PATIENTS WITH NEUROFIBROMATOSIS (LITERATURE REVIEW) В мире научных открытий нейрофиброматоз NF1 NF2 таргетная терапия |
| title | TARGET THERAPY FOR PATIENTS WITH NEUROFIBROMATOSIS (LITERATURE REVIEW) |
| title_full | TARGET THERAPY FOR PATIENTS WITH NEUROFIBROMATOSIS (LITERATURE REVIEW) |
| title_fullStr | TARGET THERAPY FOR PATIENTS WITH NEUROFIBROMATOSIS (LITERATURE REVIEW) |
| title_full_unstemmed | TARGET THERAPY FOR PATIENTS WITH NEUROFIBROMATOSIS (LITERATURE REVIEW) |
| title_short | TARGET THERAPY FOR PATIENTS WITH NEUROFIBROMATOSIS (LITERATURE REVIEW) |
| title_sort | target therapy for patients with neurofibromatosis literature review |
| topic | нейрофиброматоз NF1 NF2 таргетная терапия |
| url | http://journal-s.org/index.php/vmno/article/view/10208 |
| work_keys_str_mv | AT elenavaycheslavovnazhukovskaya targettherapyforpatientswithneurofibromatosisliteraturereview AT vladislavpavlovochbondarenko targettherapyforpatientswithneurofibromatosisliteraturereview AT irinailinichnaspichak targettherapyforpatientswithneurofibromatosisliteraturereview AT ludmilavasilevnasidorenko targettherapyforpatientswithneurofibromatosisliteraturereview |